S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

• Matteo Giovanni Della Porta,
• Uwe Platzbecker,
• Valeria Santini,
• Amer M. Zeidan,
• Pierre Fenaux,
• Rami S. Komrokji,
• Jake Shortt,
• David Valcárcel,
• Anna Jonášová,
• Sophie Dimicoli-Salazar,
• Ing Soo Tiong,
• Chien-Chin Lin,
• Jiahui LI,
• Jennie Zhang,
• Ana Carolina Giuseppi,
• Sandra Kreitz,
• Veronika Pozharskaya,
• Karen L. Keeperman,
• Shelonitda Rose,
• Jeevan K. Shetty,
• Sheida Hayati,
• Sadanand Vodala,
• Andrius Degulys,
• Stefania Paolini,
• Thomas Cluzeau,
• Guillermo Garcia-Manero

Affiliations

Matteo Giovanni Della Porta

1 Cancer Center IRCCS Humanitas Research Hospital, Milan, Italy

Uwe Platzbecker

3 Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

Valeria Santini

4 MDS Unit, Hematology, University of Florence, AOUC, Florence, Italy

Amer M. Zeidan

5 Yale School of Medicine and Yale Cancer Center, Yale University, Department of Internal Medicine, New Haven, CT, United States

Pierre Fenaux

6 Hôpital Saint-Louis, Service d’Hématologie Séniors, Université Paris 7, Paris, France

Rami S. Komrokji

7 Moffitt Cancer Center, Tampa, FL, United States

Jake Shortt

8 Monash University and Monash Health, Melbourne, VIC, Australia

David Valcárcel

9 Hospital Universitari Vall d’Hebron, Barcelona, Spain

Anna Jonášová

10 Charles University General University Hospital, Medical Department Hematology, Prague, Czech Republic

Sophie Dimicoli-Salazar

11 Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Ing Soo Tiong

12 The Alfred, Malignant Haematology & Stem Cell Transplantation, Melbourne, VIC, Australia

Chien-Chin Lin

13 National Taiwan University Hospital, Department of Laboratory Medicine, Taipei, Taiwan

Jiahui LI

14 Bristol Myers Squibb, Princeton, NJ, United States

Jennie Zhang

14 Bristol Myers Squibb, Princeton, NJ, United States

Ana Carolina Giuseppi

15 Bristol Myers Squibb, Princeton, NJ, United States

Sandra Kreitz

16 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Veronika Pozharskaya

15 Bristol Myers Squibb, Princeton, NJ, United States

Karen L. Keeperman

15 Bristol Myers Squibb, Princeton, NJ, United States

Shelonitda Rose

15 Bristol Myers Squibb, Princeton, NJ, United States

Jeevan K. Shetty

16 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Sheida Hayati

14 Bristol Myers Squibb, Princeton, NJ, United States

Sadanand Vodala

14 Bristol Myers Squibb, Princeton, NJ, United States

Andrius Degulys

17 Vilnius University Hospital Santaros Klinikos, Hematology, Oncology and Transfusion Medicine Center, Vilnius, Lithuania

Stefania Paolini

19 “Seràgnoli” Institute of Hematology, IRCCS University Hospital of Bologna, Bologna, Italy

Thomas Cluzeau

20 Université Cote d’Azur, Département d’Hématologie Clinique, CHU Nice, Nice, France

Guillermo Garcia-Manero

21 University of Texas M.D. Anderson Cancer Center, Department of Leukemia, Houston, TX, United States